- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 236081, 5 pages
Infection and Coinfection of Human Rhinovirus C in Stem Cell Transplant Recipients
1Università degli studi dell’Insubria, Via Ravasi 2, 21100 Varese, Italy
2University of Pavia, Corso Strada Nuova 65, 27100 Pavia, Italy
3Vita-Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy
4Fondazione IRCCS San Matteo Hospital, Viale Camillo Golgi 19, 21100 Pavia, Italy
Received 31 July 2012; Accepted 30 January 2013
Academic Editor: Rossana Cavallo
Copyright © 2013 Filippo Canducci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In 54 adult stem cell transplant recipients, the presence and persistence of human rhinoviruses (including the novel lineage C) were evaluated by molecular detection and phylogenetic analysis, independently from respiratory symptoms. In the same group of patients, the presence of other coinfecting respiratory pathogens, including the novel enterovirus 109, was also evaluated.
Human rhinoviruses (HRVs) are common agents of human infections . Due to their similar genomic organization, they are classified within the same family Picornaviridae together with the human enteroviruses (HEV) [2, 3]. However, the common genomic features reflect modestly the characteristics of these viruses in terms of tropism and pathogenic potential. HRVs generally cause mild infections, replicating in the upper respiratory tract, but, in infants and immunocompromised patients, HRVs can reach the lower respiratory tract causing serious illnesses and act as pathogens or copathogens in bronchitis, bronchiolitis, and pneumonia [4, 5]. Recently a new HRV lineage designated HRV-C has been identified using molecular methods and associated with severe clinical presentations in infants and immunocompromised adults . The majority of HEVs instead replicate in the gastrointestinal tract, eventually spreading to other organs such as the heart or the central nervous system giving rise to serious diseases. Only a few HEV genotypes can occasionally be identified in the respiratory secretions of patients with lower respiratory tract infections [5, 7]. Moreover, a novel HEV (HEV 104) was identified in Switzerland and later in other countries often in association with respiratory signs [7, 8]. Finally, a novel HEV (HEV 109) was molecularly identified in the nose and throat swab samples collected between June 2007 and June 2008 from children enrolled in a cohort study of influenza-like illness in Nicaragua, in some cases also associated with enteric symptoms .
In the present study, the prevalence and persistence and the pathogenic potential of HRVs were retrospectively evaluated by molecular analysis and phylogenetic reconstruction in sequential nasopharyngeal aspirates obtained from immunosuppressed hematopoietic stem cell transplantation adult recipients. In the same cohort the presence of other coinfecting respiratory pathogens, including the novel HEV 109, was also evaluated.
A total of 175 archived respiratory samples (nasopharyngeal aspirates) were obtained from 50 allogeneic and 4 autologous haematopoietic stem cell transplant recipient patients recruited at the Division of Hematology, IRCCS Policlinico San Matteo (Pavia, Italy) regardless of respiratory symptoms, as described [10, 11]. Respiratory samples were consecutively obtained after informed consent from October 1st, 2004 to April 2007. From one to nine samples from each patient were collected every 30 days up to 180 days after transplantation. At each time point all the clinical data were collected. RNA was purified from all samples using the Qiagen RNA mini kit (Qiagen, Germany) following the manufacturer protocol. To investigate HRV infections, all samples, were subjected to first round amplification after sample extraction using Primers P1-1 (CAA GCA CTT CTG TYW CCC C) and P3-1 (ACG GAC ACC CAA AGT AG); and semi-nested amplification was performed using forward primer P1-1 and three reversed primers P2-1 (CAA GCA CTT CTG TYW CCC C), P2-2 (TTA GCC ACA TTC AGG AGC C) and P2-3 (TTA GCC GCA TTC AGG GG) as described previously . Since HEV 109 was initially cross-amplified also with the previous amplification protocol (designed to amplify the widest number of Picornaviruses), we decided to further evaluate HEV 109 prevalence by using specific primers targeting the NTR region of HEV 109 (EV109 VP1 123F, 5′-GGA GAC TGG AGC AAC TAG TAA AG-3′; EV109 VP1 363R, 5′-GGT GAA CAT TTC CAA TTT CCT ACG-3′).
All the amplification products were sequenced bidirectionally to confirm amplification specificity and virus typing by phylogenetic analysis. Molecular identification and typing of enterovirus and rhinovirus positive samples were performed with MEGA 3.1 software after ClustalW alignment and manual sequence editing with BioEdit. Phylogenetic relationships were estimated using MEGA V3.1 (neighbor-joining method by using Tajima-Nei model as estimated by using Modeltest; the α value used in MEGA was previously estimated directly from the data by using PAUP).
Since multiple infections are frequently detected in respiratory samples of patients with respiratory symptoms and to better clarify the pathogenetic role of picornaviruses in coinfections, all specimens positive for HRVs or HEV 109, were also assayed for the presence of other thirteen respiratory viruses, including parainfluenza viruses (PIV 1–3), influenza A and B viruses, human metapneumovirus (hMPV), human respiratory syncytial virus (hRSV), and adenoviruses, using a multiplex PCR strategy (Seeplex RV12 ACE Detection, Seegene, Rockville). Moreover, rhinovirus positive samples were also tested for human bocaviruses (hBoV), human coronaviruses (hCoV) and of the recently identified WU and KI polyomaviruses, using protocols described previously [13, 14].
3. Results and Discussion
Thirty seven out of the 175 samples (from 23 transplant patients) tested positive for HRV infection.
Eight of the 23 HRV positive patients were also coinfected by one or more respiratory virus (Table 1); thirteen of the 23 patients were asymptomatic. Subtyping of HRV samples allowed to identify 15 HRV-A strains, 1 HRV-B strain, and 7 HRV belonging to the novel C lineage (Table 1 and Figure 1). In 2 out of the 7 HRV-C samples coinfections with hMPV or hCoV were identified and both were symptomatic. All of the other monoinfected HRV-C positive samples were asymptomatic. Finally, 8 out of the 15 HRV-A strains and the HRV-B strains resulted to be associated with upper respiratory symptoms such as rhinorrhea, pharingodinia or tussis, being 4 of them coinfected with other pathogens.
The novel HEV 109 could be identified in a symptomatic immunocompromised adult from a respiratory sample collected at the beginning of 2006. The tedious pharngodynia suffered by this patient in the absence of other coinfecting respiratory viruses suggests a direct pathogenetic role of this virus as speculated in initial observations . Overall, HRV infections were common and frequently asymptomatic in this group of patients, including the majority of rhinoviruses infections due to HRV-C strains. In two patients with rhinorrhea, the HRV-C strains were detected together with other coinfecting viral pathogens. These results do not confirm the previously observed high pathogenic potential of this lineage, at least in immunocompromised hosts .
As previously documented for hMPV infections in immunocompromised patients [10, 11], not only sequential infections by different HRV subtypes were identified (patients 10 and 16), but long (up to 45 days) viral shedding was observed in four out of 23 patients (patients 1, 3, 18, and 22) not constantly associated with symptoms. Nevertheless as recently suggested, symptomatic or asymptomatic viral infections can trigger acute rejection and obliterative bronchiolitis in lung transplant recipients and warrant a continuous monitoring in immunocompromised patients, with methods able to identify an always wider panel of potential viral pathogens .
F. Canducci and M. Debiaggi contributed equally to this study.
The authors are grateful to Rosa Angela Pignataro for sample sequencing.
- A. C. Palmenberg, D. Spiro, R. Kuzmickas et al., “Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution,” Science, vol. 324, no. 5923, pp. 55–59, 2009.
- B. A. Brown, K. Maher, M. R. Flemister et al., “Resolving ambiguities in genetic typing of human enterovirus species C clinical isolates and identification of enterovirus 96, 99 and 102,” Journal of General Virology, vol. 90, no. 7, pp. 1713–1723, 2009.
- M. S. Oberste, S. Peñaranda, K. Maher, and M. A. Pallansch, “Complete genome sequences of all members of the species human enterovirus A,” Journal of General Virology, vol. 85, no. 6, pp. 1597–1607, 2004.
- Z. Piotrowska, M. Vázquez, E. D. Shapiro et al., “Rhinoviruses are a major cause of wheezing and hospitalization in children less than 2 years of age,” Pediatric Infectious Disease Journal, vol. 28, no. 1, pp. 25–29, 2009.
- B. Winther, F. G. Hayden, and J. O. Hendley, “Picornavirus infections in children diagnosed by RT-PCR during longitudinal surveillance with weekly sampling: association with symptomatic illness and effect of season,” Journal of Medical Virology, vol. 78, no. 5, pp. 644–650, 2006.
- S. K. P. Lau, C. C. Y. Yip, H. W. Tsoi et al., “Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children,” Journal of Clinical Microbiology, vol. 45, no. 11, pp. 3655–3664, 2007.
- C. Tapparel, T. Junier, D. Gerlach et al., “New respiratory enterovirus and recombinant rhinoviruses among circulating picornaviruses,” Emerging Infectious Diseases, vol. 15, no. 5, pp. 719–726, 2009.
- A. Piralla, F. Rovida, F. Baldanti, and G. Gerna, “Enterovirus genotype EV-104 in humans, Italy, 2008-2009,” Emerging Infectious Diseases, vol. 16, no. 6, pp. 1018–1021, 2010.
- N. L. Yozwiak, P. Skewes-Cox, A. Gordon et al., “Human enterovirus 109: a novel interspecies recombinant enterovirus isolated from a case of acute pediatric respiratory illness in Nicaragua,” Journal of Virology, vol. 84, no. 18, pp. 9047–9058, 2010.
- M. Debiaggi, F. Canducci, M. Sampaolo et al., “Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients,” Journal of Infectious Diseases, vol. 194, no. 4, pp. 474–478, 2006.
- M. Debiaggi, F. Canducci, C. Terulla et al., “Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients,” New Microbiologica, vol. 30, no. 3, pp. 255–258, 2007.
- B. H. Tan, L. H. Loo, E. A. S. Lim et al., “Human rhinovirus group C in hospitalized children, Singapore,” Emerging Infectious Diseases, vol. 15, no. 8, pp. 1318–1320, 2009.
- F. Canducci, M. Debiaggi, M. Sampaolo et al., “Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease,” Journal of Medical Virology, vol. 80, no. 4, pp. 716–723, 2008.
- M. Debiaggi, F. Canducci, R. Brerra et al., “Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients,” Journal of Medical Virology, vol. 82, no. 1, pp. 153–156, 2010.
- D. Kumar, S. Husain, M. H. Chen et al., “A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients,” Transplantation, vol. 89, no. 8, pp. 1028–1033, 2010.